Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 117-121 , 30 October 2009

Interferon-beta therapy for multiple sclerosis — Is the injection site the relevant action site?

  • Derek Smith

      Affiliations

    • Corresponding Author InformationTel.: +1 860 886 1433; fax: +1 860 886 4644.

Received 21 February 2009 ,Revised 17 July 2009 ,Accepted 18 August 2009.

References 

  1. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD 4 ligand. Proc. Natl. Acad. Sci. 1997;94:599–603
  2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  3. Bartholome EJ, Willems F, Crusiaux A, Thielemans K, Schandene L, Goldman M. IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion. J. Interferon Cytokine Res. 1999;19:471–478
  4. Betaseron [package insert]. 2008. Bayer HealthCare Pharmaceuticals Inc. Montville, NJ.
  5. Bos JD. Skin Immune System. New York, NY: CRC Press; 2004;
  6. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J. Interferon Cytokine Res. 2000;20:857–866
  7. Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, et al. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J. Neuroimmunol. 2005;168:175–182
  8. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 1997;49:1111–1116
  9. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm. Res. 1993;10:567–572
  10. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 2007;79:43–72
  11. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol. Cell Biol. 2002;80:497–505
  12. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–748
  13. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann. Neurol. 2009;65:499–509
  14. Fajardo-Moser M, Berzel S, Moll H. Mechanisms of dendritic cell-based vaccination against infection. Int. J. Med. Microbiol. 2008;298:11–20
  15. Fujita H, Asahina A, Tada Y, Fujiwara H, Tamaki K. Type I interferons inhibit maturation and activation of mouse Langerhans cells. J. Invest. Dermatol. 2005;125:126–133
  16. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun. Rev. 2007;6:169–175
  17. Gigli G, Caielli S, Cutuli D, Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology. 2007;122:409–417
  18. Huang YM, Hussien Y, Yarilin D, Xiao BG, Liu YJ, Link H. Interferon-beta induces the development of type 2 dendritic cells. Cytokine. 2001;13:264–271
  19. Hussien Y, Sanna A, Soderstrom M, Link H, Huang YM. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J. Neuroimmunol. 2001;121:102–110
  20. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000;343:898–904
  21. Jacobs LD, Cookfair DL, Rudick RA, et al. The Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996;39:285–294
  22. Janeway CA, Travers P, Walport M, Schlomchik MJ. T cell-mediated immunity. In: Immunobiology. New York, NY: Garland Science; 2005;
  23. Kappos L, Freedman MS, Polman CH, et al. BENEFIT Study Group Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–397
  24. Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 2006;177:4196–4202
  25. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult. Scler. 2008;14:622–630
  26. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. T-cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T-cell repertoire. Annu. Rev. Immunol. 2002;20:101–123
  27. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 2004;4:211–222
  28. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005;201:233–240
  29. Larregina AT, Falo LD. Changing paradigms in cutaneous immunology: adapting with dendritic cells. J. Invest. Dermatol. 2005;124:1–12
  30. Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin. Immunol. 2007;19:48–55
  31. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996;40:846–852
  32. Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain. 2007;130:490–501
  33. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalitis. Nat. Med. 2002;8:500–508
  34. Martín-Saavedra FM, González-García C, Bravo B, Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 2008;45:4008–4019
  35. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007;8:913–919
  36. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin. Immunol. 2007;19:372–376
  37. McRae BL, Semnani RT, Hayes MP, van Seventer GA. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 1998;160:4298–4304
  38. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255–258
  39. Miller LS, Modlin RL. Toll-like receptors in the skin. Semin. Immunopathol. 2007;29:15–26
  40. Nagai T, Devergne O, van Seventer GA, van Seventer JM. Interferon-beta mediates opposing effects on interferon-gamma-dependent interleukin-12 p70 secretion by human monocyte-derived dendritic cells. Scand. J. Immunol. 2007;65:107–117
  41. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 1993;151:6535–6545
  42. Nestle FO, Nickoloff BJ. Deepening our understanding of immune sentinels in the skin. J. Clin. Invest. 2007;117:2382–2385
  43. Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J. Neurol. Sci. 2007;259:27–37
  44. Pashenkov M, Teleshova N, Kouwenhoven M, Kostulas V, Huang YM, Soderstrom M, et al. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis. Clin. Exp. Immunol. 2002;127:519–526
  45. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504
  46. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183–1186
  47. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 1996;40:618–627
  48. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T-cell-mediated tissue damage. Nat. Med. 2007;13:139–145
  49. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996;40:853–863
  50. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277–1285
  51. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liquori M, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing–remitting MS. Neurology. 1999;53:1402–1408
  52. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008;172:146–155
  53. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 2006;176:7768–7774
  54. Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Astier AL, Weiner HL. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J. Neuroimmunol. 2008;195:140–145
  55. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin. Immunol. 2005;17:273–283
  56. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453:106–109
  57. Wiesemann E, Sonmez D, Heidenreich F, Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T cells. J. Neuroimmunol. 2002;123:160–169
  58. Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult. Scler. 2004;10:499–506
  59. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta 1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J. Immunol. 2009;182:3928–3936

PII: S0165-5728(09)00312-9

doi: 10.1016/j.jneuroim.2009.08.011

Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 117-121 , 30 October 2009

Article Tools

* Image Usage & Resolution